Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers
Clinical Pharmacology in Drug Development · 2024-08 · 13 (8) · 884-889
DOI: 10.1002/cpdd.1432 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 10.06.2024. Verfasst von Sheng He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Zhejiang Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Vardenafil Dihydrochloride. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Vardenafil hydrochloride tablet is an inhibitor of phosphodiesterase type 5, primarily for the treatment of erectile dysfunction. This postprandial study evaluated the pharmacokinetics and bioequivalence of the test and reference formulations of vardenafil hydrochloride tablets in healthy Chinese volunteers. An open, randomized, single‐center, single‐dose, 2‐period, 2‐sequence bioequivalence test was conducted on 66 healthy subjects under fed conditions. Subjects were randomly assigned to a 20‐mg test or reference formulation with a 7‐day washout period. Venous blood samples (4 mL) were collected from each subject 25 times spanning predose (0 hour) to 24 hours after dosing. The plasma concentration of vardenafil was determined by high‐performance liquid chromatography‐tandem mass spectrometry. Sixty‐two volunteers completed the study. Under fed conditions, the maximum plasma concentration was 29.1 ng/mL, the area under the concentration–time curve (AUC) from time 0 to the time of the last measurable concentration was 85.3 ng•h/mL, and AUC from time 0 to infinity was 87.1 ng•h/mL. The 90% confidence intervals of the geometric mean ratio of AUC time 0 to the time of the last measurable concentration and AUC from time 0 to infinity were within the bioequivalence acceptance range of 0.80‐1.25. The test formulation was a bioequivalent alternative to the reference formulation when taken under fed conditions in healthy Chinese subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Zhejiang Hospital, Hangzhou, China.
- Phase I Clinical Trial Center, Zhejiang Hospital, Hangzhou, China.
- Nanjing Jiening Pharmaceutical Technology Co., Ltd, Nanjing, China.
- Yangtze River Pharmaceutical Group Co., Ltd, Taizhou, China.
- Department of Nephrology, Zhejiang Hospital, Hangzhou, China.
Zitieren
APA
He, S., Wu, X., Zhang, W., Wang, K., Chen, Y., Zheng, Z., Zhang, T., Chen, L., Duan, Q., He, D., & Wu, B. (2024). Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 13(8), 884-889. https://doi.org/10.1002/cpdd.1432
Vancouver
He S, Wu X, Zhang W, Wang K, Chen Y, Zheng Z, et al. Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2024;13(8):884-889. doi:10.1002/cpdd.1432
BibTeX
@article{He2024,
author = {He, Sheng and Wu, Xinyi and Zhang, Wanggang and Wang, Keli and Chen, Yu and Zheng, Zhibo and Zhang, Ting and Chen, Lili and Duan, Qingqing and He, Dongyuan and Wu, Binbin},
title = {Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {8},
pages = {884--889},
doi = {10.1002/cpdd.1432}
}
EUVIMED